Study No. P030098

Table 15 - continued Histopathological findings
Male, Female, 52w

Organs and findings	Sex	Male					Female									
	Group and dose	100 mg/kg					Control					4 mg/kg				
	Number of animals	10					10					10				
		-	+	++	+++	Total	-	+	++	+++	Total	-	+	++	+++	Total
Special sense organs																
Eye				(10)					(10)					(0)		
Atrophy, retina, focal		10	0	0	0	0	10	0	0	0	0					
Dysplasia, retina		10	0	0	0	0	10	0	0	0	0					
Mineralization, cornea		9	1	0	0	1	10	0	0	0	0					
Harderian gland				NR(10)					NR(10)					(0)		
Musculoskeletal system																
M. biceps femoris				NR(10)					NR(10)					(0)		
Sternum				NR(10)					NR(10)					(0)		
Femur				NR(10)					NR(10)					(0)		
Integumentary system																
Integument				(10)					(10)					(0)		
Cellular infiltration, mononuclear cell, subcutis		9	1	0	0	1	10	0	0	0	0					
Keratoacanthoma		10	0	0	0	0	10	0	0	0	0					
Others																
Extremity				(4)					(2)					(0)		
Formation, callus, hindlimb		4	0	0	0	0	2	0	0	0	0					
Ulcer, hindlimb		0	4	0	0	4	0	2	0	0	2					

Not significantly different from control.
Grade sign: -, none; +, mild (existence of tumor); ++, moderate; +++, marked.
NR: no remarkable changes.
Figures in parentheses are number of animals with tissues examined histopathologically.

Table 15 - continued Histopathological findings
Male, Female, 52w

Organs and findings	Sex	Female									
	Group and dose	20 mg/kg					100 mg/kg				
	Number of animals	9					10				
		-	+	++	+++	Total	-	+	++	+++	Total
Digestive system											
Tongue				(0)					NR(10)		
Esophagus				(0)					NR(10)		
Stomach				(0)					(10)		
Dilatation, glandular space, glandular stomach							7	3	0	0	3
Duodenum				(9)					(10)		
Accumulation, foam cell, lamina propria	9	0	0	0	0		9	1	0	0	1
Jejunum				(9)					(10)		
Accumulation, foam cell, lamina propria	9	0	0	0	0		4	6	0	0	6**
Ileum				(9)					(10)		
Accumulation, foam cell, lamina propria	9	0	0	0	0		9	1	0	0	1
Accumulation, foam cell, peyer's patch	9	0	0	0	0		9	1	0	0	1
Cecum				(0)					NR(10)		
Colon				(0)					NR(10)		
Rectum				(0)					NR(10)		
Submaxillary gland				(0)					NR(10)		
Sublingual gland				(0)					NR(10)		
Parotid gland				(0)					NR(10)		
Liver				(9)					(10)		
Degeneration, hepatocyte, fatty, centrilobular	9	0	0	0	0		10	0	0	0	0
Degeneration, hepatocyte, fatty, periportal	7	2	0	0	2		3	3	4	0	7*
Necrosis, hepatocyte, focal	9	0	0	0	0		10	0	0	0	0
Hypertrophy, hepatocyte, centrilobular	5	4	0	0	4*		0	0	10	0	10**
Hyperplasia, bile duct	7	2	0	0	2		9	1	0	0	1
Hematopoiesis, extramedullary	9	0	0	0	0		10	0	0	0	0
Focus, altered cell, basophilic	9	0	0	0	0		10	0	0	0	0
Focus, altered cell, clear	9	0	0	0	0		10	0	0	0	0
Angiectasis	9	0	0	0	0		10	0	0	0	0
Hemorrhage	9	0	0	0	0		10	0	0	0	0
Cellular infiltration, mononuclear cell	9	0	0	0	0		10	0	0	0	0
Accumulation, foam cell, sinusoid[a]	8	1	0	0	1		1	7	2	0	9**
Cholangioma	9	0	0	0	0		10	0	0	0	0

*: P<0.05, **: P<0.01 (significantly different from control).
Grade sign: -, none; +, mild (existence of tumor); ++, moderate; +++, marked.
NR: no remarkable changes.
a) with lymphocyte infiltration.
Figures in parentheses are number of animals with tissues examined histopathologically.
One female in the 20 mg/kg group died.

Table 15 - continued Histopathological findings
Male, Female, 52w

Study No.P030098

Organs and findings	Sex	Female									
	Group and dose	20 mg/kg					100 mg/kg				
	Number of animals	9					10				
		-	+	++	+++	Total	-	+	++	+++	Total
Digestive system											
Pancreas				(0)					(10)		
Atrophy, acinus, focal							10	0	0	0	0
Hyperplasia, acinar cell, focal							10	0	0	0	0
Focus, acinar cell, basophilic							10	0	0	0	0
Metaplasia, hepatocyte							10	0	0	0	0
Hemorrhage							10	0	0	0	0
Polyarteritis							10	0	0	0	0
Respiratory system											
Trachea				(0)					NR(10)		
Lung				(0)					(10)		
Metaplasia, osseous							10	0	0	0	0
Accumulation, foam cell, alveolus							10	0	0	0	0
Mineralization, artery							9	1	0	0	1
Hematopoietic system											
Thymus				(0)					(10)		
Atrophy							0	8	2	0	10
Submaxillary lymph node				(0)					NR(10)		
Mesenteric lymph node				(9)					(10)		
Accumulation, foam cell	6	3	0	0		3	0	4	6	0	10**
Spleen				(9)					(10)		
Hematopoiesis, extramedullary	8	1	0	0		1	10	0	0	0	0
Cyst, capsule	9	0	0	0		0	10	0	0	0	0
Accumulation, foam cell, white pulp	9	0	0	0		0	6	4	0	0	4*
Accumulation, foam cell, red pulp	9	0	0	0		0	6	4	0	0	4*
Bone marrow (sternum)				(0)					NR(10)		
Bone marrow (femur)				(0)					NR(10)		
Cardiovascular system											
Heart				(0)					(10)		
Cellular infiltration, mononuclear cell							9	1	0	0	1
Fibrosis, myocardium							10	0	0	0	0

*: $P<0.05$, **: $P<0.01$ (significantly different from control).
Grade sign: -, none; +, mild (existence of tumor); ++, moderate; +++, marked.
NR: no remarkable changes.
Figures in parentheses are number of animals with tissues examined histopathologically.
One female in the 20 mg/kg group died.

Study No. P030098

Table 15 - continued Histopathological findings
Male, Female, 52w

Organs and findings	Sex	Female									
	Group and dose	20 mg/kg					100 mg/kg				
	Number of animals	9					10				
		-	+	++	+++	Total	-	+	++	+++	Total
Cardiovascular system											
Aorta				(0)					NR(10)		
Urinary system											
Kidney				(9)					(10)		
Hyperplasia, transitional epithelium, pelvis		8	1	0	0	1	10	0	0	0	0
Tubule, basophilic		6	3	0	0	3	5	5	0	0	5*
Karyomegaly, epithelial cell, proximal tubule		9	0	0	0	0	10	0	0	0	0
Droplet, epithelial cell, proximal tubule, hyaline		9	0	0	0	0	10	0	0	0	0
Cast, proteinaceous		6	3	0	0	3	6	4	0	0	4
Dilatation, distal tubule		8	1	0	0	1	10	0	0	0	0
Dilatation, pelvic cavity		9	0	0	0	0	10	0	0	0	0
Cyst, medulla		9	0	0	0	0	10	0	0	0	0
Hemorrhage, pelvis		8	1	0	0	1	10	0	0	0	0
Cellular infiltration, mononuclear cell, pelvis		9	0	0	0	0	10	0	0	0	0
Cellular infiltration, mononuclear cell, cortex		9	0	0	0	0	10	0	0	0	0
Cellular exudation, pelvic cavity, neutrophil		9	0	0	0	0	10	0	0	0	0
Mineralization, pelvis		7	2	0	0	2	10	0	0	0	0
Mineralization, cortex		9	0	0	0	0	10	0	0	0	0
Mineralization, medulla		2	7	0	0	7*	6	4	0	0	4
Urinary bladder				(0)					NR(10)		
Genital system											
Testis				NA					NA		
Atrophy, seminiferous tubule											
Edema, interstitium											
Epididymis				NA					NA		
Decrease, sperm, lumen											
Prostate				NA					NA		
Cellular infiltration, mononuclear cell											
Fibrosis, interstitium											
Seminal vesicle				NA					NA		
Ovary				(0)					NR(10)		

*: P<0.05 (significantly different from control).
Grade sign: -, none; +, mild (existence of tumor); ++, moderate; +++, marked.
NR: no remarkable changes.
NA: not applicable.
Figures in parentheses are number of animals with tissues examined histopathologically.
One female in the 20 mg/kg group died.

Table 15 - continued Histopathological findings
Male, Female, 52w

Organs and findings	Sex	Female									
	Group and dose	20 mg/kg					100 mg/kg				
	Number of animals	9					10				
		-	+	++	+++	Total	-	+	++	+++	Total
Genital system											
Uterus		(0)							(10)		
Metaplasia, epithelial cell, gland, squamous							8	2	0	0	2
Cyst, endometrium							9	1	0	0	1
Vagina		(0)							(10)		
Degeneration, epithelium, mucous							9	1	0	0	1
Mammary gland		(0)							(10)		
Ectasia, alveolus/duct							4	3	3	0	6
Adenoma							9	1	0	0	1
Endocrine system											
Pituitary		(0)							(10)		
Hyperplasia, anterior lobe, focal							10	0	0	0	0
Cyst, anterior lobe							10	0	0	0	0
Hemorrhage, Rathke's pouch							10	0	0	0	0
Gliosis, posterior lobe							10	0	0	0	0
Ectopic tissue, posterior lobe							9	1	0	0	1
Adenoma, anterior lobe							10	0	0	0	0
Thyroid		(0)							(10)		
Hyperplasia, C cell, focal							9	1	0	0	1
Remnant, ultimobranchial body							7	3	0	0	3
Parathyroid		(0)							NR(10)		
Adrenal		(0)							(10)		
Hypertrophy, cortical cell, focal							10	0	0	0	0
Hyperplasia, cortical cell, focal							7	3	0	0	3
Angiectasis							2	8	0	0	8
Nervous system											
Cerebrum		(0)							NR(10)		
Cerebellum		(0)							NR(10)		
Medulla oblongata		(0)							NR(10)		
Spinal cord		(0)							NR(10)		
Optic nerve		(0)							NR(10)		
Sciatic nerve		(0)							NR(10)		

Not significantly different from control.
Grade sign: -, none; +, mild (existence of tumor); ++, moderate; +++, marked.
NR: no remarkable changes.
Figures in parentheses are number of animals with tissues examined histopathologically.
One female in the 20 mg/kg group died.

Table 15 - continued Histopathological findings
Male, Female, 52w

Organs and findings	Sex	Female									
	Group and dose	20 mg/kg					100 mg/kg				
	Number of animals	9					10				
		-	+	++	+++	Total	-	+	++	+++	Total
Special sense organs											
Eye				(0)					(10)		
Atrophy, retina, focal							9	1	0	0	1
Dysplasia, retina							9	1	0	0	1
Mineralization, cornea							10	0	0	0	0
Harderian gland				(0)					NR(10)		
Musculoskeletal system											
M. biceps femoris				(0)					NR(10)		
Sternum				(0)					NR(10)		
Femur				(0)					NR(10)		
Integumentary system											
Integument				(0)					(10)		
Cellular infiltration, mononuclear cell, subcutis							10	0	0	0	0
Keratoacanthoma							10	0	0	0	0
Others											
Extremity				(0)					(3)		
Formation, callus, hindlimb							2	1	0	0	1
Ulcer, hindlimb							1	2	0	0	2

Not significantly different from control.
Grade sign: -, none; +, mild (existence of tumor); ++, moderate; +++, marked.
NR: no remarkable changes.
Figures in parentheses are number of animals with tissues examined histopathologically.
One female in the 20 mg/kg group died.

Fd Chem. Toxic. Vol. 31, No. 12, pp. 929–933, 1993
Printed in Great Britain.

0278-6915/93 $6.00 + 0.00

6-3. 1,1-ビス(tert-ブチルジオキシ)-3,3,5-トリメチルシクロヘサンのがん原性試験

CARCINOGENICITY STUDY OF 1,1-BIS(*tert*-BUTYLPEROXY)-3,3,5-TRIMETHYLCYCLOHEXANE IN B6C3F$_1$ MICE

M. MITSUI, F. FURUKAWA, M. SATO, T. ENAMI, T. IMAZAWA, A. NISHIKAWA and M. TAKAHASHI*
Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158, Japan

(Accepted 14 July 1993)

Abstract—1,1-Bis(*tert*-butylperoxy)-3,3,5-trimethylcyclohexane (BBTC) is widely used in the manufacture of rubber. The present carcinogenicity study in B6C3F$_1$ mice was carried out in order to assess its potential to induce tumours. BBTC was administered at dietary levels of 0 (control), 0.25 and 0.5% for 78 wk; these dose levels were selected on the basis of a subchronic toxicity study, in which body weights were depressed to less than 90% of the control group values and swelling of hepatocytes was histologically evident in animals fed 1% BBTC or more in the diet. Neoplasms were found in all groups, including the control group, but there were no significant differences between groups of either sex in mortality, tumour incidences or tumour distribution. All tumours were considered to be spontaneous because of the similarity to background data for B6C3F$_1$ mice. This study thus provides no evidence of carcinogenicity of BBTC in B6C3F$_1$ mice.

INTRODUCTION

1,1-Bis(*tert*-butylperoxy)-3,3,5-trimethylcyclohexane (BBTC) is widely used as a source of free radicals in the hardening of unsaturated polyester resins and the polymerization of styrene, finding particular application in the rubber industry. Its chemical structure is illustrated in Fig. 1. BBTC is not mutagenic in *Salmonella typhimurium* (E. Machigaki, personal communication, 1987). Although lauroyl peroxide (another source of free radicals used as an initiator in the polymerization of vinyl chloride in rubber manufacture) has also been shown not to be mutagenic in *S. typhimurium* (Yamaguchi and Yamashita, 1980), this compound has been suspected from bioassay data to have carcinogenic potential (Kotin and Falk, 1963). In addition, other free radical sources in the plastics and rubber industries such as *tert*-butylperoxy benzoate (Kotin and Falk, 1963) and benzoyl peroxide (Slaga *et al.*, 1981) have been shown to exert skin tumour-promoting activities or to be suspected carcinogens in preliminary animal studies.

Because BBTC has not been sufficiently examined for its possible toxicity and carcinogenicity despite its wide industrial use, the present investigation was carried out to assess any carcinogenic potential of the compound. This study was performed as a part of the risk re-evaluation of existing chemicals in Japan.

*To whom correspondence should be addressed.
Abbreviation: BBTC = 1,1-bis(*tert*-butylperoxy)-3,3,5-trimethylcyclohexane.

MATERIALS AND METHODS

Animals

Male and female B6C3F$_1$ mice, purchased at the age of 5 wk from Charles River Japan Inc. (Kanagawa, Japan), were maintained on basal diet (MF; Oriental Yeast Ind. Co., Tokyo, Japan) and tap water until they were 6 wk old, when the studies started.

Chemical

BBTC (CAS No. 6731-86-8), purchased from Nippon Yushi Co. (Tokyo, Japan), was in a liquid form and was over 90% pure. It was administered orally to animals in the diet as detailed below. The diet supplemented with BBTC was kept at 4°C.

Housing conditions

Mice were housed 10 to a plastic cage, with softwood chips as bedding. The room was maintained at a temperature of 23 ± 2°C and a humidity of 55 ± 5%, with a 12-hr light/dark cycle.

Experimental design

A preliminary subchronic toxicity study was carried out prior to the carcinogenicity study.

Subchronic toxicity study. BBTC was added to MF powdered basal diet and fed *ad lib.* to groups of 10 male and 10 female mice at dietary concentrations of 0.5, 1.0, 2.0 or 4.0% for 13 wk. Control animals received the basal diet without BBTC. Throughout the experiment, mice were given tap water *ad lib.* Animals were observed daily for clinical signs and



Fig. 1. Chemical structure of 1,1-bis(*tert*-butylperoxy)-3,3,5-trimethylcyclohexane (BBTC).

deaths were recorded. At the end of the experiment, all surviving mice were killed, and major organs/tissues were taken for gross and microscopic examination. The results were used to determine appropriate dose levels for the subsequent carcinogenicity study.

Carcinogenicity study. Mice were divided randomly into three groups, each consisting of 50 males and 50 females. BBTC was added to the powdered basal diet at 0 (control), 0.25 or 0.5%. These dose levels were selected according to the results of the subchronic toxicity study. Animals were given their respective diet *ad lib.* for 78 wk, and the amounts of food consumed were measured in order to calculate the actual intakes of BBTC. Throughout the experiment, mice had free access to tap water. All mice were observed daily for clinical signs and deaths were recorded. Body weights were measured once a week for the first 13 wk of the study and then once every 4 wk. After 78 wk, the administration of BBTC was stopped and mice were then maintained on the powdered basal diet until wk 83 when all surviving animals were killed. All mice found dead, killed when moribund or killed at the end of the study were completely autopsied, and their organs were fixed routinely in 10% buffered formalin, sectioned and stained with haematoxylin and eosin.

Statistical analysis. Data were analysed for statistical significance by Fisher's exact probability test and the chi-square test.

RESULTS

Subchronic toxicity study

Two males and two females given 4.0% BBTC died during the study, all other mice survived until wk 13. Throughout the experiment, body weight gain and food consumption in the BBTC-treated groups were lower than those of the controls. For both sexes, the only dose of BBTC at which final body weights were in excess of 90% of the control values was 0.5%. Haematological examinations showed a tendency of anaemia in groups of both sexes receiving 1.0% BBTC or more. Relative liver weights were significantly increased in BBTC-treated mice in a dose-dependent manner. In contrast, absolute and relative spleen weights were decreased in a dose-dependent manner. Histopathological examinations revealed swelling of hepatocytes in male and female mice fed 1.0% BBTC or more, and atrophy of the red and white pulp in the spleen as well as a decrease of haematopoietic cells in the bone marrow were observed in males given 2.0 or 4.0% BBTC and in females fed 4.0% BBTC. From these results it was concluded that, with particular consideration given to growth retardation and histopathological findings, the maximum long-term dose of dietary BBTC that can be tolerated would be 0.5% for mice of both sexes. Therefore, 0.25 and 0.5% were selected as



Fig. 2. Growth curves of B6C3F$_1$ mice given 1,1-bis(*tert*-butylperoxy)-3,3,5-trimethylcyclohexane in the diet for 78 wk at 0 (males, ○; females, ●), 0.25 (males, △; females, ▲) or 0.5% (males, □; females, ■). Surviving mice were observed for a further 10 wk and killed at 83 wk.

Table 1. Total tumour incidences, food consumption, 1,1-bis(*tert*-butylperoxy)-3,3,5-trimethylcyclohexane (BBTC) intake, final survival rate and mean survival time of B6C3F$_1$ mice given BBTC in the diet for 78 wk

BBTC dose (%)	No. of mice			Food consumption (g/animal/day)	Mean total BBTC intake (g/kg body weight/78 wk)	Final survival rate (%)	Mean survival time and range (wk)
	Initial	Effective	With tumour				
Males							
0	50	49	29	5.6	0	98.0	83.0 (82–83)
0.25	50	48	30	5.1	187	95.8	80.8 (23–83)
0.5	50	50	30	4.7	373	94.0	82.4 (61–83)
Females							
0	50	50	19	6.3	0	94.0	80.6 (15–83)
0.25	50	49	18	6.1	280	94.8	81.9 (47–83)
0.5	50	50	21	5.9	576	96.0	82.7 (73–83)

appropriate dose levels for the subsequent carcinogenicity study.

Carcinogenicity study

Growth and mortality. The growth curves (Fig. 2) showed a dose-dependent inhibitory effect of BBTC on the growth of mice of both sexes in the 0.25 and 0.5% groups. The survival rates and mean survival times (Table 1), however, indicated no significant differences between groups of either sex.

Tumour incidence and BBTC intake. Overall tumour incidences and total intakes of BBTC are summarized in Table 1. There were no significant differences in total tumour incidences between groups of either sex. Total intakes of BBTC, estimated from the food consumption data, were dose related.

Distribution and histopathology. The sites, histological types and incidences of tumours in each group are summarized in Table 2. Tumours were found in various organs from mice of both sexes in each group, including the control group. However, all the tumours were considered to be spontaneous because their incidences were essentially similar to those of spontaneous neoplastic lesions reported previously in

Table 2. Sites and types of tumours in B6C3F$_1$ mice given 1,1-bis(*tert*-butylperoxy)-3,3,5-trimethylcylohexane (BBTC) in the diet for 78 wk

Site and type of tumour	No. of mice with tumours					
	Males			Females		
BBTC dose (%)...	0	0.25	0.5	0	0.25	0.5
Effective no. of mice	48	47	50	47	47	50
Lung						
Alveolar/bronchiolar adenoma	1	2	1	1	1	1
Alveolar/bronchiolar carcinoma	5	4	0*	0	1	0
Spleen						
Haemangioma	1	0	0	0	0	0
Haemangiosarcoma	1	0	0	1	0	0
Haematopoietic system						
Lymphoma	6	5	8	13	12	11
Histiocytic sarcoma	1	0	0	0	2	2
Small intestine						
Adenoma	0	1	0	0	0	0
Adenocarcinoma	0	1	0	0	0	0
Liver						
Hepatocellular adenoma	15	20	20	0	0	0
Hepatocellular carcinoma	8	7	7	0	0	0
Haemangioma	0	1	0	0	0	0
Haemangiosarcoma	1	1	0	0	0	0
Pancreas						
Acinar cell adenoma	0	0	0	0	0	1
Islet cell adenoma	1	1	0	0	0	0
Kidney						
Renal cell carcinoma	1	0	0	0	0	0
Adrenal gland						
Phaeochromocytoma	0	0	2	0	0	1
Cortical adenoma	0	0	0	0	1	1
Thyroid gland						
Follicular cell adenoma	0	0	0	1	0	0
Pituitary gland						
Adenoma (pars distalis)	0	0	0	1	0	0
Uterus						
Endometrial stromal polyp	—	—	—	1	0	0
Endometrial stromal sarcoma	—	—	—	1	1	2
Harderian gland						
Adenoma	5	3	0*	2	2	4
Adenocarcinoma	1	0	1	0	0	1
Skin/subcutis						
Schwannoma, malignant	0	1	0	0	0	0
Mastocytoma	0	0	0	0	0	1

*Significantly different from control group ($P < 0.05$).

Table 3. Incidences of total tumours and malignant tumours in B6C3F$_1$ mice given 1,1-bis(*tert*-butylperoxy)-3,3,5-trimethylcyclohexane (BBTC) in the diet for 78 wk

Parameter	Males			Females		
BBTC dose (%)	0	0.25	0.5	0	0.25	0.5
Effective no. of mice	49	48	50	50	49	50
No. of mice with tumours	29	30	30	19	18	21
Tumours/animal	0.94	0.94	0.78	0.42	0.41	0.48
No. of mice with malignant tumours	22	16	15	14	15	15
Malignant tumours/animal	0.49	0.39	0.32	0.30	0.33	0.30

B6C3F$_1$ mice (Tamano *et al.*, 1988; Ward *et al.*, 1979). BBTC treatment did not increase the incidences of any benign or malignant tumours (Table 3). Although the incidences of lymphomas and those of lung and Harderian gland tumours in both sexes, and liver tumours in males were relatively high in the control group compared with background data, there were no significant differences. Interestingly, the incidences of lung carcinomas and Harderian gland adenomas in male mice were decreased in a dose-dependent manner with statistical significance in the high-dose group.

Non-neoplastic lesions. Although non-neoplastic lesions were observed frequently in all groups, including the controls, no significant differences were found between groups. Swelling of centrilobular hepatocytes, as observed in the subchronic toxicity study, was evident only in male mice fed 0.5% BBTC.

DISCUSSION

Tumours of the liver, haematopoietic organs, lung and Harderian gland are known to develop spontaneously in mice of the B6C3F$_1$ strain (Tamano *et al.*, 1988; Ward *et al.*, 1979). In the present study, BBTC administration neither increased the incidences of such spontaneous tumours nor induced any unusual neoplasms. Slight but significant decreases in the incidences of lung carcinomas and Harderian gland adenomas were associated with BBTC treatment. With regard to lung carcinomas, similar results have previously been reported for cyclohexane (Lijinsky and Kovatch, 1986). The present results therefore suggest that BBTC may inhibit directly the development of some spontaneous tumours; however, the dose-dependent decreases in food consumption and body weight gain in the BBTC-treated groups may have acted as factors that suppress tumour development. Based on the fact that the incidences of both lung and Harderian gland tumours in the control group were elevated compared with earlier background data (Tamano *et al.*, 1988; Ward *et al.*, 1979), together with the finding that the total tumour incidences were similar to those found in previous studies (Tamano *et al.*, 1988; Ward *et al.*, 1979), the inhibitory effects were likely to be of little significance, if any.

Peroxides are widely used as a source of free radicals in various industries. Recently, free radicals have been suggested to play important biological roles, especially in carcinogenic processes. In fact, some peroxides such as *tert*-butylperoxy benzoate and benzoyl peroxide, which are functionally similar to BBTC, are known to be mutagenic (Mortelmans *et al.*, 1986; Saladino *et al.*, 1985) and carcinogenic (Kotin and Falk, 1963) or co-carcinogenic (Slaga *et al.*, 1981). The hepatotoxicity and haematotoxicity of BBTC were noted in the present subchronic toxicity study, but no nephrotoxicity was observed, despite the finding that cyclohexane and tetramethylcyclohexanes, which have structural resemblances to BBTC, are nephrotoxic in rats (Bernard *et al.*, 1989; Johannsen and Levinskas, 1987). The observed hepatotoxicity could have been caused by the induction of cytochrome *P*-450 enzyme activity, since it has been shown that the structurally similar hexachlorocyclohexane induces this activity in the liver (Popp and Cattley, 1991). Persistent induction of the cytochrome *P*-450 enzyme may give rise to subsequent hepatocarcinogenesis. The haematotoxicity might have been caused primarily by the damage of the haematopoietic organs, although nutritional impairment could, to some extent, contribute to its occurrence. Despite the cytotoxicity in the liver and haematopoietic organs, there were no significant increases caused by BBTC in the incidences of neoplasms in these organs.

It was therefore concluded that BBTC exerts no carcinogenic activity in B6C3F$_1$ mice. However, while cyclohexane has been suspected as a mutagen from the results of DNA–cell binding assays (Kubinski *et al.*, 1981) and is also known to be a skin tumour promoter in mice, it is not a complete carcinogen (Gupta and Mehrottra, 1990). Thus, although BBTC has been shown not to be mutagenic in the Ames test, the possibility that it can act as a tumour promoter requires further elucidation.

Acknowledgement—This work was supported by a Grant-in-Aid for Safety Evaluation of Existing Chemicals from the Ministry of Health and Welfare of Japan.

REFERENCES

Bernard A. M., de Russus R., Normand J. C. and Lauwerys R. R. (1989) Evaluation of the subacute nephrotoxicity of cyclohexane and other industrial solvents in the female Sprague–Dawley rat. *Toxicology Letters* **45**, 271–280.

Gupta K. P. and Mehrottra N. K. (1990) Mouse skin ornithine decarboxylase induction and tumor promotion by cyclohexane. *Cancer Letters* **51**, 227–233.

Johannsen F. R. and Levinskas G. J. (1987) Acute and subchronic toxicity of tetramethylcyclohexanes. *Journal of Applied Toxicology* **7**, 245–248.

Kotin P. and Falk H. L. (1963) Organic peroxides, hydrogen peroxide, epoxides, and neoplasia. *Radiation Research Supplement* **3**, 193–211.

Kubinski H., Gutzke G. E. and Kubinski Z. O. (1981) DNA-cell binding assay for suspected carcinogens and mutagens. *Mutation Research* **89**, 95–136.

Lijinsky W. and Kovatch R. M. (1986) Chronic toxicity study of cyclohexane in rats and mice. *Journal of the National Cancer Institute* **77**, 941–949.

Mortelmans K., Hawarth S., Lawlor T., Speck W., Tainer B. and Zeiger E. (1986) Salmonella mutagenicity tests. II. Results from the testing of 270 chemicals. *Environmental Mutagenicity* **8**, (Suppl. 7), 1–26.

Popp J. A. and Cattley R. C. (1991) Hepatobiliary System. In *Handbook of Toxicologic Pathology*. Edited by W. M. Haschek and R. C. Cattley. pp. 279–314. Academic Press, New York.

Saladino A. J., Willey J. C., Lechner J. F., Grafstrom R. C., LaVeck M. and Harris C. C. (1985) Effects of formaldehyde, benzoyl peroxide, and hydrogen peroxide on cultured normal human bronchial epithelial cells. *Cancer Research* **45**, 2522–2526.

Slaga J. J., Klein-Szanto A. J. P., Triplett L. L. and Yotti L. P. (1981) Skin tumor producing activity of benzoyl peroxide, a widely used free radical generating compound. *Science* **213**, 1023–1024.

Tamano S., Hagiwara A., Shibata M., Kurata Y., Fukushima S. and Ito N. (1988) Spontaneous tumors in aging (C57BL/6N × C3H/Hen)F_1 (B6C3F_1) mice. *Toxicologic Pathology* **16**, 321–326.

Ward J. M., Goodman D. G., Squire R. A., Chu K. C. and Linhart M. S. (1979) Neoplastic and nonneoplastic lesions in aging (C57BL/6N × C3H/Hen)F_1 mice. *Journal of the National Cancer Institute* **63**, 849–854.

Yamaguchi T. and Yamashita Y. (1980) Mutagenicity of hydroperoxides of fatty acids and some hydrocarbons. *Agricultural Biology and Chemistry* **44**, 1675–1678.

6-4. 1,1-ビス(tert-ブチルジオキシ)-3,3,5-トリメチルシクロヘサン のその他の毒性情報

他の毒性情報	[三井ら：衛生試験所報告,110, 42-47,1992 より引用] 反復投与毒性試験 B6C3F$_1$ マウス　(0.5, 1.0, 2.0, 4.0%(混餌投与))　13 週間　純度 90%以上 {♂：800, 1500, 3200, 6000 mg/kg/day 相当、 ♀：1000, 1700, 3100, 6500 mg/kg/day 相当} NOEL：<0.5%(800 mg/kg/day) 死亡(4.0：♂8/10・♀8/10) 一般状態（削痩：2.0 以上♂♀） 体重↓(1.0 以上♂♀) 摂餌量↓：0.5 以上♂♀ 血液学的検査(Hgb↓・MCV↓：2.0♂♀、Hct↓・WBC↓：2.0♂) 相対重量(肝↑：0.5 以上♂♀) 病理組織学的所見(肝－小葉中心性細胞肥大：1.0 以上♂♀、 骨髄－造血細胞減少／うっ血：2.0 以上♂♀、 脾－白脾髄／赤脾髄萎縮：2.0 以上♂・4.0♀)

18-1. 2,4-ジ-tert-ブチル-6-(5-クロロ-2H-1,2,3-ベンゾトリアゾール-2-イル)フェノールの ReproTox 試験

8. 要約

8.1 成績概要表 1

2-(3, 5-ジ-tert-ブチル-2-ヒドロキシフェニル)-5-クロロベンゾトリアゾール(DBHCB)のラットにおける強制経口投与による 28 日間反復投与毒性/生殖発生毒性併合試験

試験系		ラット，雄：5 週齢			
被験物質		対照 a)	DBHCB		
投与量（mg/kg/日）		0	2.5	25	250
投与液量（mL/kg/日）		10	10	10	10
濃度（mg/mL）		0	0.25	2.5	25
動物数（毒性群，休薬群）		10，5	10	10	10，5
死亡数		0	0	0	0
一般状態	投与期間	-	-	-	-
	休薬期間	-			-
体重	投与期間	-	-	-	-
	休薬期間	-			-
摂餌量	投与期間	-	17-18 日↓	-	28-29 日↓
	休薬期間				
剖検	投与期間終了時	-	-	-	肺:赤色巣(1)
	休薬期間終了時	肺:赤色巣(1)			-
器官重量	投与期間終了時	-	-	肝臓（絶，相）↑	肝臓（絶，相）↑
	休薬期間終了時	-			心臓（絶，相）↑ 肝臓（絶，相）↑
血液学的検査	投与期間終了時	-	-	活性化部分トロンボプラスチン時間↓	活性化部分トロンボプラスチン時間↓ 好中球数↑ 赤血球数↓
	休薬期間終了時	-			好中球数↑ 好中球（%）↑ リンパ球（%）↓ 血小板数↑

-：対照群との間に有意な差なし，あるいは異常所見なし.

↑：統計学的に有意な高値，↓：統計学的に有意な低値.

a：5 w/v%アラビアゴム水溶液,

絶：絶対重量，相：相対重量.

成績概要表（続き）

2-（3, 5-ジ-tert-ブチル-2-ヒドロキシフェニル）-5-クロロベンゾトリアゾール（DBHCB）のラットにおける強制経口投与による28日間反復投与毒性/生殖発生毒性併合試験

試験系		ラット，雄：5週齢			
被験物質		対照 a)	DBHCB		
投与量（mg/kg/日）		0	2.5	25	250
動物数（毒性群，休薬群）		10，5	10	10	10，5
血液生化学的検査	投与期間終了時	-	β - グロブリン比率↓	アルブミン↑ アルブミン比率↑ A/G 比↑ クレアチニン↓ α_2 - グロブリン比率↓ β - グロブリン比率↓ ALAT↑ 総蛋白↑ Ca↑	アルブミン↑ アルブミン比率↑ A/G 比↑ クレアチニン↓ α_2 - グロブリン比率↓ β - グロブリン比率↓ ALP↑ 総ビリルビン↓
	休薬期間終了時	-			アルブミン↑ クレアチニン↓ α_2 - グロブリン比率↓ 総蛋白↑ 総コレステロール↑

-：対照群との間に有意な差なし，あるいは異常所見なし．

↑：統計学的に有意な高値，↓：統計学的に有意な低値．

a：5 w/v%アラビアゴム水溶液．

成績概要表（続き）

2-（3, 5-ジ-tert-ブチル-2-ヒドロキシフェニル）-5-クロロベンゾトリアゾール（DBHCB）のラットにおける強制経口投与による28日間反復投与毒性/生殖発生毒性併合試験

試験系			ラット，雄：5週齢			
被験物質			対照 a)	DBHCB		
投与量（mg/kg/日）			0	2.5	25	250
動物数（毒性群）			5	5	5	5
病理組織学的検査 b)	投与期間終了時 b)	副腎	束状帯細胞の空胞化			
			左:2/5，右:2/5			左:2/5，右:2/5
		心臓	心室心筋の繊維化			
			左:1/5			左:1/5
			心室心筋の単核細胞浸潤			
			右:1/5			左:2/5
		腎臓 c)	尿細管の好塩基性変化			
			左:3/5，右:1/5			左:3/5，右:2/5
		肺 d)	肺胞の泡沫細胞蓄積			
			左: 2/5，右:1/5			左:1/5，右:2/5
			血管周囲の炎症細胞浸潤			
			-			右:1/5
		肝臓 e)	単核細胞浸潤			
			2/5	2/5	2/5	1/5
			限局性胆管の増殖			
			-	-	-	1/5

-：対照群との間に有意な差なし，あるいは異常所見なし．

a：5 w/v%アラビアゴム水溶液．

b：投与期間終了時の病理組織学的検査で被験物質投与に起因する変化がみられなかったことから休薬期間終了時の検査は実施しなかった．

c：対照群のみに認められた変化は尿細管腔内に硝子円柱，尿細管上皮の空胞化，皮質の単核細胞浸潤，皮質の鉱質沈着であった．

d：対照群では骨化生，動脈壁の鉱質沈着，肺胞の単核細胞浸潤がみられた．

e：対照群では空胞化がみられた．

成績概要表（続き）

2-（3,5-ジ-tert-ブチル-2-ヒドロキシフェニル）-5-クロロベンゾトリアゾール（DBHCB）のラットにおける強制経口投与による28日間反復投与毒性/生殖発生毒性併合試験

試験系		ラット，雌：5週齢			
被験物質		対照[a]	DBHCB		
投与量（mg/kg/日）		0	2.5	25	250
動物数（毒性群，休薬群）		10，5	10	10	10，5
死亡数		0	0	0	0
一般状態	投与期間	-	-	-	-
	休薬期間	-			-
体重	投与期間	-	17-21日増加量↑	-	-
	休薬期間	-			-
摂餌量	投与期間	-	-	-	31-32日↑
	休薬期間				
剖検	投与期間終了時	-	-	-	-
	休薬期間終了時	-			-
器官重量	投与期間終了時	-	肝臓（相）↓	-	-
	休薬期間終了時	-			-
血液学的検査	投与期間終了時	-	-	好酸球数↓	好酸球数↓
	休薬期間終了時	-			-
血液生化学的検査	投与期間終了時	-	総コレステロール↓	総コレステロール↓	-
	休薬期間終了時	-			-

-：対照群との間に有意な差なし，あるいは異常所見なし.

↑：統計学的に有意な高値，↓：統計学的に有意な低値.

a：5 w/v%アラビアゴム水溶液,

相：相対重量.

成績概要表（続き）

2-（3, 5-ジ-tert-ブチル-2-ヒドロキシフェニル）-5-クロロベンゾトリアゾール（DBHCB）のラットにおける強制経口投与による28日間反復投与毒性/生殖発生毒性併合試験

試験系			ラット，雌：5週齢			
被験物質			対照[a]	DBHCB		
投与量（mg/kg/日）			0	2.5	25	250
動物数（毒性群）			5			5
死亡数			0	0	0	0
病理組織学的検査[b]	投与期間終了時[b]	腎臓[c]	皮質髄質境界部の鉱質沈着			
			-			左:1/5，右:1/5
		肺[d]	肺胞の泡沫細胞蓄積			
			左:1/5，右:1/5			左:1/5，右:2/5
			動脈壁の鉱質沈着			
			-			右:3/5
		気管	線毛上皮の扁平上皮化生			
			1/5			-
		腸間膜リンパ節	樹状細胞様細胞の増加			
			-			1/5
		肝臓	単核細胞浸潤			
			1/5	1/5	2/5	-
			空胞化			
			1/5	1/5	-	-

-：対照群との間に有意な差なし，あるいは異常所見なし．

a：5 w/v%アラビアゴム水溶液．

b：投与期間終了時の病理組織学的検査で被験物質投与に起因する変化がみられなかったことから休薬期間終了時の検査は実施しなかった．

c：対照群では皮質の単核細胞浸潤，尿細管の好塩基性変化，腎盂腔内の異物，腎盂移行上皮の好酸球浸潤がみられた．

d：対照群では血管周囲の炎症細胞浸潤，肺胞上皮の増殖，肉芽種がみられた．